Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Teva bids for BioXcel's neuroscience product
PRIVATEAug 28, 2026•about 3 hours ago
Acquiring Company
Teva Pharmaceuticals International GmbH
Acquired Company
BioXcel Therapeutics
Tel AvivNew HavenManufacturingBiotechnologyHealth CarePharmaceutical
Description
Teva Pharmaceuticals has announced a bid to acquire an innovative neuroscience product from BioXcel Therapeutics. This asset, a dexmedetomidine sublingual film, is under review by the FDA for treatment of agitation in patients with schizophrenia or bipolar disorder. The acquisition aims to enhance Teva's portfolio and address unmet needs in mental health care.
Company Information
Company
Teva Pharmaceuticals International GmbH
Location
Tel Aviv, Tel-Aviv District, Israel
About
Teva Pharmaceuticals International GmbH is a subsidiary of Teva Pharmaceutical Industries Ltd., a global leader in generic and specialty medicines. The company specializes in the development and distribution of high-quality biosimilars and has a robust infrastructure for delivering innovative healthcare solutions. Teva is committed to enhancing patient access to essential medications. The company's portfolio includes a wide range of biosimilars that are pivotal in treating various medical conditions.
Don't miss Teva Pharmaceuticals International GmbH's next move
Get an email the moment Teva Pharmaceuticals International GmbH makes an acquisition, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Predictive Intelligence
Strategic
ML-powered predictions for Teva Pharmaceuticals International GmbH's next move
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed
Frequently asked
Who acquired BioXcel Therapeutics?
BioXcel Therapeutics was acquired by Teva Pharmaceuticals International GmbH, based in Tel Aviv. The deal was reported on August 28, 2026. Teva Pharmaceuticals International GmbH is a subsidiary of Teva Pharmaceutical Industries Ltd., a global leader in generic and specialty medicines. Teva Pharmaceuticals International GmbH is privately held and operates in Manufacturing.
When did Teva Pharmaceuticals International GmbH acquire BioXcel Therapeutics?
Teva Pharmaceuticals International GmbH's acquisition of BioXcel Therapeutics was reported on August 28, 2026. Teva Pharmaceuticals has announced a bid to acquire an innovative neuroscience product from BioXcel Therapeutics. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does BioXcel Therapeutics do?
It is privately held, and is based in New Haven.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
Tel Aviv
New HavenManufacturingBiotechnologyHealth CarePharmaceutical